TD Cowen on MapLight Therapeutics (MPLT): 'tolerability looked favorable'

July 27, 2026 9:49 AM EDT Send to a Friend
TD Cowen analyst Joseph Thome reiterated a Buy rating on MapLight Therapeutics (NASDAQ: MPLT).The analyst comments "Maplight announced that the ...

This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE

Member Login